• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Karen Flynn to Board of Directors

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTLT alert in real time by email

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

    Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer health products. Prior to this, she held the positions of Chief Commercial Officer and President of Biologics at Catalent. Prior to Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services (NYSE:WST), and as President of its Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation and quality management.

    "We are excited to welcome Karen to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Karen's extensive commercial expertise in pharmaceutical services will serve as a tremendous asset as we continue to grow. Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company."

    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (NASDAQ:QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent. She has also served on the Board of Recro Pharma, Inc., a specialty pharma and contract development and manufacturing organization, where she was Chair of the Compensation Committee and a member of the Audit Committee.

    Ms. Flynn holds a Master of Science in Engineering from University of Pennsylvania and a Master of Science in Business Administration from Boston University. She completed her Bachelor of Science at the University of Notre Dame.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts

    Jason Peterson

    Vice President & Treasurer, Sotera Health

    [email protected]

    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $CTLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTLT
    $QTRX
    $SHC
    $WST

    CompanyDatePrice TargetRatingAnalyst
    Sotera Health Company
    $SHC
    5/5/2025$17.00Neutral → Buy
    Goldman
    West Pharmaceutical Services Inc.
    $WST
    3/18/2025$275.00Outperform
    Evercore ISI
    West Pharmaceutical Services Inc.
    $WST
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    West Pharmaceutical Services Inc.
    $WST
    1/8/2025$400.00Buy
    Citigroup
    West Pharmaceutical Services Inc.
    $WST
    12/13/2024Peer Perform
    Wolfe Research
    West Pharmaceutical Services Inc.
    $WST
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    Sotera Health Company
    $SHC
    12/6/2024$14.00Neutral
    Goldman
    Sotera Health Company
    $SHC
    5/21/2024$13.00Neutral
    Piper Sandler
    More analyst ratings